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Abstract Stable angina pectoris affects 2–4 % of the popula-
tion in Western countries and entails an annual risk of death
and nonfatal myocardial infarction of 1–2 % and 3 %, respec-
tively. Heart rate (HR) is linearly related tomyocardial oxygen
consumption and coronary blood flow, both at rest and during
stress. HR reduction is a key target for the prevention of
ischemia/angina and is an important mechanism of action of
drugs which are recommended as first line therapy for the
treatment of angina in clinical guidelines. However, many
patients are often unable to tolerate the doses of beta blocker
or non-dihydropyridine calcium antagonists required to
achieve the desired symptom control. The selective pacemak-
er current inhibitor ivabradine was developed as a drug for the
management of patients with angina pectoris, through its abil-
ity to reduce HR specifically. The available data suggest that
ivabradine is a well-tolerated and effective anti-anginal agent
and it is recommended as a second-line agent for relief of
angina in guidelines. However, recent clinical trials of
ivabradine have failed to show prognostic benefit and have
raised potential concerns about safety. This article will review
the available evidence base for the current role of ivabradine
in the management of patients with symptomatic angina
pectoris in the context of stable coronary artery disease.
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Stable coronary artery disease
Background
Coronary artery disease (CAD) is the global leading cause of
mortality, accounting for approximately 7.4 million deaths an-
nually. Furthermore, CAD accounts for a high morbidity rate,
poor quality of life with a major socioeconomic impact. Stable
angina pectoris affects 2–4 % of the population in Western
countries, with prevalence increasing with age [1]. It entails
an annual risk of death and nonfatal myocardial infarction
(MI) of 1–2 % and 3 %, respectively [2, 3]. Optimal medical
treatment (OMT), the cornerstone of stable CAD (SCAD)man-
agement, should be routinely offered to patients with SCAD to
relieve angina and improve prognosis [3–5]. Guidelines recom-
mend that OMT should comprise 2 anti-anginal drugs, one of
which should be a beta blocker or calcium antagonist, in addi-
tion to disease modifying medications that are known to reduce
risk of death and myocardial infarction (aspirin, statins and
ACE inhibitors) [3–5]. Ivabradine is recommended as a
second-line agent for relief of angina. This article will review
the evidence base supporting the use of ivabradine in the man-
agement of patients with SCAD.
Heart Rate as a Therapeutic Target in SCAD
Angina pectoris is principally caused by myocardial ischae-
mia, which arises from a mismatch between myocardial oxy-
gen supply and demand. Relief of angina can be achieved
pharmacologically by redressing this imbalance. Myocardial
oxygen demand is mainly determined by the frequency and
force of myocardial contraction. Heart rate (HR) is linearly
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related to myocardial oxygen consumption and coronary
blood flow, both at rest and during stress. Furthermore, since
myocardial perfusion occurs predominantly during diastole,
there is an inverse relationship between the perfusion time
and HR, with subendocardial perfusion being particularly sen-
sitive to increased HR [6, 7].
Increased HR commonly precedes effort-induced ischemia
and the frequency of ischaemic episodes is twice as high in
patients with a resting HR >80 bpm as compared to those with
HR <70 bpm. In addition, increased HR is an independent risk
factor for ischaemia-triggered arrhythmia, infarct size and mor-
tality [7]. Therefore, decreasing HR is a rational strategy to
reduce myocardial ischaemia and prevent the development of
symptomatic angina. In patients with previous MI, mortality
was observed to increase when HR exceeded 60 bpm, [8] which
has informed guideline recommendations to aim for a target HR
of 55–60 bpm in patients with SCAD [3, 4]. Both beta blockers
and non-dihydropyridine calcium antagonists reduce HR, with
the degree of angina reduction being directly related to the mag-
nitudes of HR reduction [8]. However, many patients cannot
tolerate the doses of beta blocker required to achieve the desired
level of HR reduction [9, 10] and non-DHP calcium antagonists
should be avoided in patients with low blood pressure, left ven-
tricular dysfunction or heart failure. Therefore drugs which se-
lectively reduce HR and which are well tolerated would repre-
sent a biologically plausible and important therapeutic develop-
ment for the management of patients with SCAD.
Pharmacology and Anti-Ischaemic Action
of Ivabradine
The Bfunny^ current (If) was identified within sinoatrial nodal
cells and discovered to be primarily responsible for the spon-
taneous diastolic depolarisation that characterises pacemaker
cells. The If current, also known as the Bpacemaker current^,
consists of mixed sodium–potassium ion influx which is acti-
vated during diastolic hyperpolarisation, thereby initiating di-
astolic depolarisation, the slope of which determines the sino-
atrial node automaticity and hence sinus HR [11]. In addition
to being located in the sinoatrial node, If channels are
expressed throughout the cardiac conduction system, includ-
ing the atrioventricular node and Purkinje fibres, where they
are activated at more negative voltages. More recently, If chan-
nels have also been identified in the myocardial sleeves ex-
tending around the pulmonary veins [12, 13].
Ivabradine is the only clinically approved If current inhib-
itor. It produces a dose-dependent, selective, inhibition of the
If current by binding to the cation channel pore in its open
conformation, thereby decreasing the slope of diastolic
depolarisation, prolonging sinus nodal cell recovery time
and decreasing HR (Fig. 1) [14, 15]. The magnitude of HR
reduction is greatest in individuals with the highest resting HR
[16, 17]. Ivabradine-induced HR reduction is not subject to
tolerance and occurs at concentrations that do not interfere
with other ionic channels. In contrast to beta blockers and
non-DHP-calcium channel blockers, ivabradine-induced HR
reduction at clinically approved doses does not affect myocar-
dial contractility, atrioventricular conduction or ventricular
repolarisation [1, 11]. Ivabradine induced heart rate reduction
has been shown to improve diastolic dysfunction and amelio-
rate myocardial hypoxia in experimental models [15].
Mechanistic studies also suggest potential additional
modes of benefit of ivabradine. In comparison with
bisoprolol, ivabradine treatment was associatedwith increased
maximal hyperaemic flow and coronary flow reserve, despite
a similar reduction in HR [15]. This may be explained by
increased diastolic perfusion time, enhanced isovolumic con-
traction and recruitment of collateral flow. Studies in a mouse
model of hind limb ischaemia suggest that ivabradine promotes
Fig. 1 Mechanism of action of ivabradine on sinoatrial If current. a |
Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels
allow the passage of the funny current (If), which is a major current
producing slow diastolic depolarization of the sinoatrial pacemaker
potential. The other currents contributing to diastolic depolarization are
omitted. Ivabradine (‘Iv’) blocks HCN channels and reduces the slope of
diastolic depolarization, thereby reducing the frequency of sinoatrial
pacemaker potentials. b | Current-dependent block of HCN channels by
ivabradine. Ivabradine enters the pore of HCN channels from the
intracellular aspect when the channels are in the open conformation (left
side of panel). When the membrane potentials are more positive than ~
−20 mV, HCN-mediated currents are mainly carried by K+ and outwardly
directed. The outward current drives ivabradine into the pore of the
channel, where it binds tightly to a specific site (right side of panel).
The polarity of the plasma membrane is indicated by ‘+’ or ‘−’ signs.
The movement of the positively charged S4 helix of HCN channels in the
electrical field is also indicated. Reproduced from [14]
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angiogenesis [18] and recent invasive assessments of collateral
function in patients with SCAD suggest that HR reduction by
ivabradine is associated with prolongation of diastolic perfu-
sion and improved collateral function, potentially through al-
tered tangential shear force at the endothelial surface or en-
hanced vascular stretch which may both promote arteriogenesis
[19]. Ivabradine induced HR reduction may also have a direct
anti-atherogenic effect and improve endothelial dysfunction
[20, 21]. In a porcine model of acute ischaemia, ivabradine
induced improvements in myocardial blood flow and wall
thickening in the ischaemic zone could be reversed through
atrial pacing, but the reduction in infarct size could not [22].
Inhibition of If channels at the level of the ventricular myocyte
may confer a direct cardioprotective effect through enhanced
cardiac myocyte viability, attenuation of mitochondrial produc-
tion of reactive oxygen species, and improved calcium han-
dling, suggesting pleiotropic benefits of ivabradine treatment
which are independent of HR reduction [23]. Recent data sug-
gest that ivabradine treatment may attenuate post-ischaemic
myocardial stunning [24, 25] and therefore may potentially
prevent deterioration of left ventricular dysfunction due to the
development of myocardial hibernation, which is thought to
result from repeated episodes of myocardial stunning [26].
Pharmacokinetics, Drug Interactions
and Tolerability
Ivabradine is rapidly absorbed after oral administration with
linear pharmacokinetics in the dose range of 0.5–24 mg [27].
Under fasting conditions, the time to peak drug concentration is
approximately 1 h, with an absolute bioavailability of film-
coated tablets of ~40 % following both gastrointestinal and
hepatic first-pass metabolism. By contrast, in fed conditions,
the time to peak plasma drug concentration is prolonged by
approximately 1 h with the plasma concentration being ~20–
30 % higher. Approximately 70 % of ivabradine is plasma
protein bound. Ivabradine has a half-life of 2 h in plasma and
a biological half-life of 11 h, resulting in a significant reduction
in HR with preservation of diurnal heart rate variation (Fig. 2).
Approximately 4 % of a single oral ivabradine dose is excreted
unchanged in urine. Renal impairment has minor impact on the
pharmacokinetics of both ivabradine and its mainmetabolite, as
renal clearance accounts for only ~20 % of the elimination of
both products, though care should be taken in patients with
advanced renal dysfunction. Patients with mild hepatic impair-
ment require no dose adjustment. Ivabradine may be used with
care in patients with moderate hepatic impairment, but is con-
traindicated in cases of severe hepatic insufficiency. No signif-
icant differences in the pharmacokinetic profile of ivabradine
have been observed with age, though dosing should be judi-
cious in patients aged >75 years.
Ivabradine is extensively metabolised by the cytochrome
P450 (CYP) enzyme CYP3A4. It is a very weak inhibitor of
this enzyme and does not appear to influence metabolism and
plasma concentrations of other CYP3A4 substrates. By con-
trast, CYP3A4 inhibitors and agonists have been demonstrat-
ed to alter ivabradine plasma concentrations. The concomitant
use of moderate or strong CYP3A4 inhibitors (e.g. non-
dihydropyridine calcium antagonists, macrolide antibiotics,
anti-retroviral drugs, anti-fungals) is contraindicated. Proton
pump inhibitors, sildenafil, 3-hydroxy-3-methyl-glutaryl-
CoA (HMG-CoA) reductase inhibitors, dihydropyridine
calcium-channel blockers, digoxin and warfarin have not
demonstrated any clinically significant effect on the pharma-
cokinetics and pharmacodynamics of ivabradine.
Fig. 2 Change from baseline in
mean heart rate over 24 h after
treatment with ivabradine7.5 mg
twice daily in volunteers. Bpm,
beats per minute. Clinical data
from the IRIS trial. EudraCT
record 2011–001,665-40 (data on
file). Reproduced from [65]
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Ivabradine is generally well-tolerated in both clinical trials
and real world observational studies, and described in greater
detail below. Common minor side-effects are mainly visual
(phosphenes, blurred vison and occasionally stroboscopic ef-
fects) and gastrointestinal. These are generally mild, transient
and rarely require treatment discontinuation. The commonest
cardiac side-effects are bradycardia (asymptomatic and symp-
tomatic), atrial fibrillation and QT prolongation, though after
correction for heart rate, QTc is only modestly increased and
should not significantly increase risk of torsade de pointes
[28]. Side effect profiles in the context of reported clinical
trials will be discussed in greater detail below.
Ivabradine as Monotherapy
The first randomised placebo-controlled trial of ivabradine in
patients with stable angina was reported in 2003, in which
ivabradine at doses of 5 and 10 mg twice daily was superior
to placebo in reducing HR, frequency of angina episodes and
the use of short-acting nitrates, while increasing exercise tol-
erance and time to onset of ischemia on treadmill exercise
testing, in a dose-dependent fashion [29].
The anti-ischaemic and anti-anginal effects of ivabradine
(7.5 mg BD and 10 mg BD) were compared with atenolol
(100 mg OD) in the randomised double blind INITIATIVE
trial. In this study, ivabradine monotherapy was demonstrated
to be non-inferior to atenolol for increasing total exercise dura-
tion, time to limiting angina, time to angina onset and time to
1 mm ST depression. Patients treated with ivabradine reported
decreased angina frequency and short acting nitrates (SAN) use
similar to that observed in atenolol treated patients [30].
After 3 months, ivabradine (7.5 or 10 mg BD) was non-
inferior to amlodipine (10 mg OD) for increasing total exer-
cise duration, as well as the time to onset of ischaemia and
angina on treadmill exercise testing. Both drugs produced a
60 % decrease in the frequency of angina attacks and a
50–60 % drop in the use of SAN. Compared to the
dihydropyridine-calcium channel blocker, ivabradine lowered
HR both at rest and at peak exercise with a consequent greater
reduction of the rate-pressure product [31].
These data suggest that ivabradine monotherapy is equiv-
alent to guideline recommended first-line drugs for improving
angina symptoms and exercise testing parameters in patients
with SCAD.
Ivabradine as Add-On Therapy in Patients
with SCAD
As discussed above, increased heart rate is a major determi-
nant of myocardial ischemia [32] and has been a major target
for pharmacologic intervention. Beta blockers are the
exemplar negatively chronotropic drugs and are recommend-
ed as first-line therapy for angina in both European and US
clinical guidelines. However, beta blockers at target dose are
often poorly tolerated [33], which can result in suboptimal
heart rate control and persistent anginal symptoms requiring
the use of additional pharmacologic agents. There is only lim-
ited evidence that the addition of long-acting nitrates,
nicorandil, or dihydropyridine calcium antagonists to beta
blocker therapy results in improved symptoms, objective
markers of myocardial ischemia, and exercise duration
[34–38]. There is, therefore, a clinical need for pharmacologic
strategies which can be safely added to beta blockade, that are
well tolerated, provide objective reduction of ischaemic bur-
den, improve exercise duration, and reduce anginal symptoms
without an increased risk of adverse events. Furthermore, ep-
idemiologic data also suggest a relationship between resting
heart rate and prognosis (all-cause death, sudden cardiac death
and fatal myocardial infarction) across the spectrum of cardio-
vascular disease [7, 39, 40]. In patients with coronary artery
disease enrolled in the CASS study, resting HR was a potent
and independent predictor of all-cause and cardiovascular
mortality [40]. In previous studies of patients with systolic
heart failure [41] or previous myocardial infarction [42], im-
proved prognosis was correlated with the magnitude of heart
rate reduction. Hypothetically, reducing heart rate has the po-
tential not only to relieve symptoms of angina but also to
improve prognosis in patients with SCAD.
Previous attempts to optimise heart rate control by adding
non-dihydropyridine calcium antagonists on top of back-
ground beta blocker therapy have been unsuccessful due to
the development of limiting side-effects [43] and should there-
fore be avoided. More recently, in the ASSOCIATE trial,
ivabradine (5 to 7.5 mg BD) as add-on therapy in patients
already established on beta blockers was effective in signifi-
cantly improving exercise duration and time to both electro-
cardiographic evidence of ischaemia and symptomatic angina
on treadmill exercise testing (Fig. 3), though the frequency of
self-reported anginal attacks was not significantly reduced
[44, 45]. Serious or symptomatic bradycardia occurred in only
1.1 % of patients. These data provided the basis for
randomised clinical trials evaluating the effect of heart rate
reduction by ivabradine on clinical outcomes in patients with
SCAD with both impaired and normal left ventricular
function.
Randomised Clinical Outcomes Trials of Ivabradine
in SCAD
The BEAUTIFUL (morBidity-mortality EvAlUaTion of the If
inhibitor ivabradine in patients with coronary disease and left-
ventricULar dysfunction) trial was an international multi-
centre randomised double-blind placebo controlled trial that
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tested the hypothesis that reduction of heart rate with
ivabradine (5 to 7.5 mg BD) in patients with SCAD and
LVEF <40 % on established standard therapy would reduce
both mortality and morbidity [46]. The primary endpoint was
the composite of cardiovascular death, admission to hospital
for acute myocardial infarction, and admission to hospital for
new-onset or worsening heart failure. The study was designed
with 90 % power to detect a 19 % difference in the primary
endpoint based on an estimated event rate of rate of 11 % at
2.25 years in the placebo group. The observed event rate was
significantly higher than predicted and the trial was modified
such that all randomised patients were followed up for
12 months. Of 12,473 patients screened to enter the study,
10,917 eligible patients were randomised to receive either
placebo (5438 patients) or ivabradine (5479 patients). Mean
HR was 71.6 bpm with 87 % of patients receiving beta
blockers at randomisation. Ivabradine therapy was well toler-
ated with symptomatic bradycardia occurring in ~5 % of pa-
tients. Ivabradine significantly reduced heart rate by ~6 bpm at
12 months compared to placebo. However, this did not trans-
late into a significant improvement in the primary endpoint
between ivabradine and placebo treated patients (15.4 % v
15.3 %, hazard ratio 1·00, 95 % CI 0·91–1·1, p = 0·94). In a
pre-specified analysis of patients with HR >70 bpm at
randomisation, there was no significant difference in the pri-
mary endpoint (hazard ratio 0·91, 95 % CI 0·81–1·04, p = 0·
17) or the secondary endpoints of cardiovascular death or
heart failure outcomes. However, the rates of non-fatal or fatal
myocardial infarction (hazard ratio 0·64, 95 % CI 0·49–0·84,
p = 0·001) and coronary revascularisation (hazard ratio 0·70,
95 % CI 0·52–0·93, p = 0·016) were significantly reduced.
The authors proposed that these observed reductions in
coronary events were consistent with the hypothesis that in-
creased coronary atherogenesis [47] and risk of plaque rupture
[48], driven by higher resting HR, may be potentially attenu-
ated by ivabradine therapy.
Two major post-hoc analyses of the BEAUTIFUL trial
have been reported. The first comprised an analysis of patients
randomised to the placebo arm of the study to investigate the
relationship between resting HR and clinical outcomes [49]
and the second examined the effects of ivabradine therapy in
those patients with limiting angina [50]. In the former study
[49], the rates of cardiovascular death, hospitalisation for heart
failure, hospitalisation for myocardial infarction and coronary
revascularisation were all significantly higher in patients with
resting HR >70 bpm, with an increase of 8 % (p = 0.0005),
16 % (p < 0.0001), 7 % (p = 0.052) and 8 % (p = 0.034) for
every 5 bpm increment in HR in each of these endpoints,
respectively. These results add to the body of data supporting
the prognostic importance of increased heart rate, and in par-
ticular show a relationship between increased HR and adverse
heart failure and coronary outcomes, in patients with SCAD
and impaired LV function.
In an analysis of 1507 patients in the BEAUTIFUL trial
population with limiting angina [50], ivabradine treatment
was associated with a significant reduction in the trial primary
endpoint (hazard ratio 0.76, 95 % CI 0.58–1.00, p = 0.05) and
a significant reduction in hospitalisation for MI (hazard ratio
0.58, 95 % CI 0.37–0.92, p = 0.021) (Fig. 4). A further anal-
ysis stratified by HR >70 bpm, in addition, suggested a sig-
nificant reduction in coronary revascularisation in ivabradine
treated patients (hazard ratio 0.41, 95 % CI 0.17–0.99,
p = 0.04). These data raised the hypothesis that ivabradine
therapy may improve prognosis by reducing adverse coronary
Fig. 3 Changes in exercise
tolerance test criteria between
baseline and two month (M2)
visit and between baseline and
four month end of study (M4) in
the full analysis set of the
ASSOCIATE study. Reproduced
from [44]
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outcomes in patients with symptomatic SCAD, which has
been tested recently [51].
The Study Assessing the Morbidity–Mortality Benefits of
the If Inhibitor Ivabradine in Patients with Coronary Artery
Disease (SIGNIFY) trial was an international multi-centre
double-blind randomised placebo-controlled which recruited
19,102 patients in 51 countries with established SCAD, HR
>70 bpm and no evidence of heart failure. Patients were
randomised to receive ivabradine at an initial dose of 7.5 mg
BD (except patients >75 years old who received a dose of
5 mg BD) or placebo. The ivabradine dose could be adjusted
in the range 5-10 mg BD, to maintain a target HR of 55–
60 bpm and to avoid symptomatic bradycardia. The composite
primary endpoint consisted of death from any cause, cardio-
vascular death or non-fatal myocardial infarction. The trial
was designed to provide 90% power to detect an 18% relative
risk reduction with ivabradine, assuming an incidence of the
primary outcome of 2.7 % per year.
The mean study-drug dose was 8.2 ± 1.7 mg BD in the
ivabradine treatment arm. At 3 months, mean HR in the
ivabradine treated group was 60.7 ± 9.0 bpm compared with
70.6 ± 10.1 bpm in the placebo arm, with this difference in HR
being maintained for the duration of the study. Compliance
with study medication was high. Change in beta blocker dose
was infrequent in both study arms. Disappointingly, intention
to treat analysis of the entire study cohort failed to demonstrate
any difference in the primary composite endpoint (hazard ratio
1.08; 95 % CI 0.96–1.20, p = 0.20) (Fig. 5) or in any of the
secondary endpoints, including non-fatal myocardial infarc-
tion, between the ivabradine and placebo groups. All-cause
death, cardiovascular death and sudden death were also not
significantly different in the two groups. Angina symptoms
significantly improved in patients randomised to ivabradine
(p = 0.01) (Fig. 6), and while subsequent analyses have re-
ported better Seattle Angina Questionnaire scores, particularly
in the area of disease perception, though the domain relating to
physical limitation was not significantly impacted by
ivabradine treatment [52]. In a pre-specified subgroup analy-
sis of 12,049 patients with CCS class ≥2 angina, ivabradine
therapy was associated with an increase in the primary end-
point (7.6 %, v 6.5 % with placebo; hazard ratio, 1.18; 95 %
CI, 1.03–1.35; P = 0.02) with consistent observations for both
cardiovascular death (hazard ratio 1.16; 95% CI, 0.97 to 1.40;
P = 0.11) and non-fatal myocardial infarction (hazard ratio
1.18, 95 % CI, 0.97 to 1.42; P = 0.09) (Fig. 7). There was
no interaction between the use of ivabradine and adverse
events in other pre-specified sub-groups, defined according
to age, beta blocker use at randomisation, gender, baseline
HR, history of diabetes mellitus, previous MI, or previous
coronary revascularisation. Ivabradine treatment, compared
with placebo, was associated with significantly increased rates
of symptomatic (7.9 % v 1.2 %, p < 0.001) and asymptomatic
(11.0 % v 1.3 %, p < 0.001)) bradycardia, atrial fibrillation
(5.3 % v 3.8 %, p < 0.001) and phosphenes (5.4 % v 0.5 %,
p < 0.001). Study drug withdrawal occurred in 13.2 % of
ivabradine treated patients compared to 7.4 % in the placebo
group (p < 0.001). There was an absolute 2.2 % increase in
serious adverse events in the ivabradine treated group
(p = 0.001). Interestingly, QT interval prolongation was noted
more frequently in ivabradine treated patients (Fig. 8).
BEAUTIfUL post-hoc analysis:
Effect of ivabradine on hospitalisation for MI
in patients with CAD, LVSD and angina
Limiting angina at baseline
(n=1507)
Limiting angina and
heart rate ≥70 bpm (n=712) 
a b
Fig. 4 Post-hoc analysis demonstrating the effect of ivabradine treatment on hospitalisation for fatal and non-fatal myocardial infarction in the subgroup
of patients in the BEAUTIFUL trial with symptomatic angina (a) and the subset with HR >70 bpm (b). Adapted from [50]
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These data confirm that ivabradine significantly improves
angina in patients with SCAD but do not support the hypoth-
esis that this drug, which purely reduces heart rate, improves
prognosis in patients with SCAD. These results suggest that
HR should be considered as a biomarker of future cardiovas-
cular risk rather than a modifiable risk factor in patients with
SCAD. We will discuss further the implications of the
SIGNIFY results on the safe clinical use of ivabradine.
Real World Clinical Experience of Ivabradine
in Patients with SCAD
The open-label ADDITIONS trial evaluated the effect of add-
on ivabradine in patients who remained symptomatic with
angina despite background beta blocker therapy in routine
clinical practice [53]. In this study, ~70 % of patients had
CCS class 2 or 3 angina with 24 % of patients treated with
beta blockers at the target dose and 78 % were on at least half
the target dose. The reduction in heart rate of 19.4 ± 11.4 bpm
(p < 0.0001) observed following initiation of ivabradine was
accompanied by significantly reduced SAN use, improved
CCS class and minimal adverse events. Quality of life, as
evaluated by EQ-5D index, significantly improved by
0.17 ± 0.23 (p < 0.0001) and 97 % of physicians rated the
addition of ivabradine as having Bgood^ or Bvery good^ clin-
ical efficacy. Additional studies have suggested the safety and
clinical efficacy of ivabradine in patients in whom administra-
tion of beta blockers can be particularly challenging, including
diabetics, the elderly, peripheral artery disease, chronic ob-
structive airways disease and asthmatics [1, 54–57]. Finally,
preliminary data suggest that ivabradine may be considered to
improve symptoms and quality of life in patients with micro-
vascular angina [58], though only anecdotal evidence is cur-
rently available that shows benefit in patients with refractory
angina.
Should We Use Ivabradine for Management
of Angina Post-SIGNIFY?
The results of SIGNIFY are perplexing – patients with symp-
tomatic angina who are likely to benefit most from ivabradine
therapy simultaneously appear to be those at greatest risk of
developing adverse events. While the precise explanations for
these observations remain unknown, four issues warrant
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further consideration, namely the use of an unlicensed drug
dose, drug interactions, arrhythmia, and statistical error.
Firstly, the dosing strategy employed in the SIGNIFY trial,
significantly differs from current clinical practice, where
ivabradine is usually initiated at 2.5–5.0 mg BD and titrated
to a maximum licensed dose of 7.5 mg BD. Forty-seven per-
cent of ivabradine treated patients <75 years of age received
ivabradine at a dose of 10 mg BD. Importantly, in the pre-
specified subgroup of patients with limiting angina, the pri-
mary endpoint occurred at the 10 mg BD dosage in 58 % of
patients. In a nested case control analysis, bradycardia was
more common in patients exposed to a 10 mg BD dose of
ivabradine, with emergent bradycardia being less frequent if
ivabradine was initiated at a dose of 5 mgBD. Secondly, in the
SIGNIFY trial, 4.6 % of patients were treated with verapamil
or diltiazem, which are moderate inhibitors of CYP3A4,
resulting in ~3-fold increases in plasma ivabradine levels
and a pharmacodynamic interaction resulting in augmented
negative chronotropic effects [59]. Concurrent use of verapa-
mil or diltiazem was associated with a 68 % increase in the
primary endpoint (p = 0.088) and an 88 % increase in non-
fatal myocardial infarction (p = 0.026). These data underscore
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Fig. 7 Components of the primary composite endpoint pre-specified limiting angina subgroup in the SIGNIFY trial. Adapted from [51]
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Fig. 8 Analysis of adverse events
in the subgroup of patients with
moderate or severe angina (CCS
class II-IV) in the SIGNIFY trial.
CV, cardiovascular; MI,
myocardial infarction. Adapted
from [66]
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the importance of not co-prescribing verapamil or diltiazem
with ivabradine and underpin recent recommendations from
the Pharmacovigilance Risk Assessment Committee of the
European Medicines Agency [59]. Thirdly, there may be po-
tentially important pro-arrhythmic effects of ivabradine treat-
ment [60]. While symptomatic bradycardia was more com-
mon in ivabradine treated patients, this was not found suffi-
cient to account for the increased rate of adverse events in
either the entire study cohort or the subgroup with limiting
angina [60]. Emergent atrial fibrillation occurred in 754 pa-
tients and occurred more commonly in ivabradine treated pa-
tients. These data are consistent with recent meta-analyses
which also suggest that those with higher pre-treatment resting
HR may be at increased risk [13]. The presence of the HCN4
isoform of the If channel in myocyte sleeves surrounding the
pulmonary veins may be an important aetiological factor [14].
Notably, the rate of the primary endpoint was not significantly
increased in patients with emergent AF in either the whole
study cohort or the subgroup with limiting angina [60].
Ivabradine treatment was associated with prolongation of the
QT interval. Importantly, this was not associated with a sig-
nificant rate of drug withdrawal or ventricular tachyarrhyth-
mia. That said, ivabradine is contraindicated in patients with
long QTsyndromes and has been associated with an increased
predisposition to torsade de pointes [61–63]. Finally, it should
be emphasised that the results of subgroup analyses from trials
that fail to meet the primary endpoint should be interpreted
with caution due to the possibility of statistical error.
Over the last fifteen years, the anti-anginal efficacy of
ivabradine has been evaluated in a clinical trial program that
has recruited in excess of 35,000 patients with SCAD and
symptomatic angina, with or without left ventricular dysfunc-
tion, either as monotherapy or in addition to first line anti-
anginal drugs. That ivabradine improves symptoms but not
prognosis in patients with SCAD and preserved LV function,
does not place ivabradine in a unique position amongst drugs
which are currently recommended for the treatment of symp-
tomatic angina in clinical guidelines. There are no definitive
randomised clinical trial data which demonstrate the prognos-
tic benefits of any of the anti-anginal drugs, including beta
blockers [64]. The available data suggest that ivabradine is a
well-tolerated and effective anti-anginal agent. As recom-
mended by the Pharmacovigilance Risk Assessment
Committee of the European Medicines Agency [59], follow-
ing their scrutiny of the SIGNIFY trial data, ivabradine should
be used in patients with HR >70 bpm who are intolerant of or
remain symptomatic despite the use of first line anti-anginal
drugs. The dose of ivabradine should be up-titrated according
to patient’s symptoms rather than aiming for a specific target
HR [59]. The prescribed dose should not exceed 7.5 mg BD.
Co-prescription of ivabradine with moderate or severe inhib-
itors of CYP3A4, in particular non-dihydropyridine calcium
antagonists, is contraindicated. Patients should be carefully
monitored for the development of bradycardia and atrial fibril-
lation, and ivabradine treatment should be avoided in patients
at risk of torsade de pointes.
Ivabradine remains licensed for the treatment of symptom-
atic angina following review by the Pharmacovigilance Risk
Assessment Committee of the European Medicines Agency
[59]. Considerable further work will be needed to understand
fully the observations from the SIGNIFY trial. However, im-
portant insights have been gained into the safe and appropriate
use of ivabradine, which should still be considered a useful
therapeutic option to relieve symptoms and improve quality of
life in suitably selected patients with SCAD.
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